Clinical Trials Logo

Clinical Trial Summary

This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10 weeks with two follow-up visits and an end of study visit at week 26.


Clinical Trial Description

Active Product: HB- adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells - allogeneic) Dose: 200 million Route: Intravenous Regimen: Weeks 0, 2, 6, and 10. Placebo: Saline Solution 0.9% Dose: N/A Route: Intravenous Regimen: Weeks 0, 2, 6, and 10.Duration of administration 1 hour Laboratory Samples. Screening, Week 0, 6, and 26. Visits by Weeks Screening Week 0 - Infusion 1 Week 2 - Infusion 2 Week 6 - Infusion 3 Week 10 - Infusion 4 Week 14 - Follow Up 1 Week 20 - Follow Up 2 Week 26 - End of Study ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05126563
Study type Interventional
Source Hope Biosciences
Contact Sherry Diers, RN
Phone 3469000340
Email [email protected]
Status Recruiting
Phase Phase 2
Start date December 20, 2021
Completion date December 20, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04694768 - Implementation of Rehabilitation Program for Post COVID-19
No longer available NCT04798066 - Intermediate Size Expanded Access Protocol Evaluating HB-adMSC's for the Treatment of Post-COVID-19 Syndrome